COMBINATION OF BEVACIZUMAB, IRINOTECAN AND TEMOZOLOMIDE FOR RELAPSED OR REFRACTORY NEUROBLASTOMA: A PHASE II STUDY.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 May 2017
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan (Primary) ; Temozolomide (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 10 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 10 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 07 Jun 2016 Results (n=33) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology